New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Scientific background information on rubber granulate now available in English In December 2016, RIVM published in Dutch the results of its research into the health risks of playing sports on synthetic turf pitches with rubber granulate.
Playing sports on synthetic turf fields with rubber granulate is safe New research by the Dutch National Institute for Public Health and the Environment (RIVM) shows it is safe for people to play sports on synthetic turf fields with an infill of rubber granulate.
RIVM starts field research into rubber granulate RIVM has started to take samples of rubber granulate from 100 synthetic turf fields in the Netherlands.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
Chikungunya infections in the Caribbean region Since August 2014, there has been an increase in the number of Chikungunya patients in the Caribbean region. Travellers who visit the region can become infected there.
RIVM presents four scenarios on future public health at European Health Forum Gastein On the first day of the 17th European Health Forum Gastein (EHFG), the Dutch National Institute for Public Health and the Environment (RIVM) organises a workshop on ‘Our health in 2040’.
No new MERS patients in the Netherlands Almost two months ago, two Dutch people were diagnosed with the MERS coronavirus.